This chapter covers a range of important topics in the evaluation of the microvascular invasion (MVI) in hepatocellular carcinoma (HCC) before treatment. The malignant potential of HCC is reflected by the types of MVI such as portal venous (vp), hepatic vein (vv) or bile duct (b) infiltration. The identification of the type of MVI in HCC has a key role in decisions regarding the effective treatment of HCC. Here, we describe the possible and important predictors of MVI in HCC.

1.
Pawlik TM, Delman KA, Vauthey JN, et al: Tumor size predicts vascular invasion and histologic grade: implications for selection of surgical treatment for hepatocellular carcinoma. Liver Transpl 2005;11:1086-1092.
2.
Yamashita Y, Taketomi A, Shirabe K, et al: Outcomes of hepatic resection for huge hepatocellular carcinoma (≥ 10 cm in diameter). J Surg Oncol 2011;104:292-298.
3.
Liver Cancer Study Group of Japan: Primary liver cancer in Japan. Clinicopathologic features and results of surgical treatment. Ann Surg 1990;211:277-287.
4.
Jonas S, Bechstein WO, Steinmüller T, et al: Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001;33:1080-1086.
5.
Taketomi A, Sanefuji K, Soejima Y, et al: Impact of des-gamma-carboxy prothrombin and tumor size on the recurrence of hepatocellular carcinoma after living donor liver transplantation. Transplantation 2009;87:531-537.
6.
Choi GH, Han DH, Kim DH, et al: Outcome after curative resection for a huge (>or=10 cm) hepatocellular carcinoma and prognostic significance of gross tumor classification. Am J Surg 2009;198:693-701.
7.
Nagano Y, Tanaka K, Togo S, et al: Efficacy of hepatic resection for hepatocellular carcinomas larger than 10 cm. World J Surg 2005;29:66-71.
8.
Yamashita Y, Tsuijita E, Takeishi K, et al: Predictors for microinvasion of small hepatocellular carcinoma ≤ 2 cm. Ann Surg Oncol 2012;19:2027-2034.
9.
Liver Cancer Study Group of Japan: The General Rules for the Clinical and Pathological Study of Primary Liver Cancer, ed 5, revised version. Tokyo, Kanehara, 2009.
10.
Nakashima Y, Nakashima O, Tanaka M, Okuda K, Nakashima M, Kojiro M: Portal vein invasion and intrahepatic micrometastasis in small hepatocellular carcinoma by gross type. Hepatol Res 2003;26:142-147.
11.
Sumie S, Kuromatsu R, Okuda K, et al: Microvascular invasion in patients with hepatocellular carcinoma and its predictable clinicopathological factors. Ann Surg Oncol 2008;15:1375-1382.
12.
Shimada M, Rikimaru T, Hamatsu T, et al: The role of macroscopic classification in nodular-type hepatocellular carcinoma. Am J Surg 2001;182:177-182.
13.
Hui AM, Takayama T, Sano K, et al: Predictive value of gross classification of hepatocellular carcinoma on recurrence and survival after hepatectomy. J Hepatol 2000;33:975-979.
14.
Genda T, Sakamoto M, Ichida T, et al: Cell motility mediated by rho and Rho-associated protein kinase plays a critical role in intrahepatic metastasis of human hepatocellular carcinoma. Hepatology 1999;30:1027-1036.
15.
Inayoshi J, Ichida T, Sugitani S, et al: Gross appearance of hepatocellular carcinoma reflects E-cadherin expression and risk of early recurrence after surgical treatment. J Gastroenterol Hepatol 2003;18:673-677.
16.
Murakata A, Tanaka S, Mogushi K, et al: Gene expression signature of the gross morphology in hepatocellular carcinoma. Ann Surg 2011;253:94-100.
17.
Takamura M, Sakamoto M, Genda T, Ichida T, Asakura H, Hirohashi S: Inhibition of intrahepatic metastasis of human hepatocellular carcinoma by Rho-associated protein kinase inhibitor Y-27632. Hepatology 2001;33:577-581.
18.
Inagaki Y, Tang W, Makuuchi M, Hasegawa K, Sugawara Y, Kokudo N: Clinical and molecular insights into the hepatocellular carcinoma tumour marker des-γ-carboxyprothrombin. Liver Int 2011;31:22-35.
19.
Shah DV, Engelke JA, Suttie JW: Abnormal prothrombin in the plasma of rats carrying hepatic tumors. Blood 1987;69:850-854.
20.
Ueda N, Shiraha H, Fujikawa T, et al: Exon 2 deletion splice variant of gamma-glutamyl carboxylase causes des-gamma-carboxy prothrombin production in hepatocellular carcinoma cell lines. Mol Oncol 2008;2:241-249.
21.
Okuda H, Obata H, Nakanishi T, Furukawa R, Hashimoto E: Production of abnormal prothrombin (des-gamma-carboxy prothrombin) by hepatocellular carcinoma. A clinical and experimental study. J Hepatol 1987;4:357-363.
22.
Murata K, Suzuki H, Okano H, Oyamada T, Yasuda Y, Sakamoto A: Cytoskeletal changes during epithelial-to-fibroblastoid conversion as a crucial mechanism of des-gamma-carboxy prothrombin production in hepatocellular carcinoma. Int J Oncol 2009;35:1005-1014.
23.
Suzuki M, Shiraha H, Fujikawa T, et al: Des-gamma-carboxy prothrombin is a potential autologous growth factor for hepatocellular carcinoma. J Biol Chem 2005;280:6409-6415.
24.
Wang SB, Cheng YN, Cui SX, et al: Des-gamma-carboxy prothrombin stimulates human vascular endothelial cell growth and migration. Clin Exp Metastasis 2009;26:469-477.
25.
Liebman HA, Furie BC, Tong MJ, et al: Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 1984;310:1427-1431.
26.
Mita Y, Aoyagi Y, Yanagi M, Suda T, Suzuki Y, Asakura H: The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 1998;82:1643-1648.
27.
Kaibori M, Ishizaki M, Matsui K, Kwon AH: Predictors of microvascular invasion before hepatectomy for hepatocellular carcinoma. J Surg Oncol 2010;102:462-468.
28.
Koike Y, Shiratori Y, Sato S, et al: Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 2001;91:561-569.
29.
Fujiki M, Takada Y, Ogura Y, et al: Significance of des-gamma-carboxy prothrombin in selection criteria for living donor liver transplantation for hepatocellular carcinoma. Am J Transplant 2009;9:2362-2371.
30.
Rigo P, Paulus P, Kaschten BJ, et al: Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996;23:1641-1674.
31.
Trojan J, Schroeder O, Raedle J, et al: Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999;94:3314-3319.
32.
Khan MA, Combs CS, Brunt EM, et al: Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000;32:792-797.
33.
Torizuka T, Tamaki N, Inokuma T, et al: In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995;36:1811-1817.
34.
Hatano E, Ikai I, Higashi T, et al: Preoperative positron emission tomography with fluorine-18-fluorodeoxyglucose is predictive of prognosis in patients with hepatocellular carcinoma after resection. World J Surg 2006;30:1736-1741.
35.
Ijichi H, Shirabe K, Taketomi A, et al: Clinical usefulness of (18) F-fluorodeoxyglucose positron emission tomography/computed tomography for patients with primary liver cancer with special reference to rare histological types, hepatocellular carcinoma with sarcomatous change and combined hepatocellular and cholangiocarcinoma. Hepatol Res 2013;43:481-487.
36.
Cheung TT, Chan SC, Ho CL, et al: Can positron emission tomography with the dual tracers [11 C]acetate and [18 F]fludeoxyglucose predict microvascular invasion in hepatocellular carcinoma? Liver Transpl 2011;17:1218-1225.
37.
Kornberg A, Freesmeyer M, Bärthel E, et al: 18F-FDG-uptake of hepatocellular carcinoma on PET predicts microvascular tumor invasion in liver transplant patients. Am J Transplant 2009;9:592-600.
38.
Lee JW, Paeng JC, Kang KW, et al: Prediction of tumor recurrence by 18F-FDG PET in liver transplantation for hepatocellular carcinoma. J Nucl Med 2009;50:682-687.
39.
Shirabe K, Kajiyama K, Harimoto N, et al: Prognosis of hepatocellular carcinoma accompanied by microscopic portal vein invasion. World J Gastroenterol 2009;15:2632-2637.
40.
Hasegawa K, Kokudo N, Imamura H, et al: Prognostic impact of anatomic resection for hepatocellular carcinoma. Ann Surg 2005;242:252-259.
41.
Shi M, Guo RP, Lin XJ, et al: Partial hepatectomy with wide versus narrow resection margin for solitary hepatocellular carcinoma: a prospective randomized trial. Ann Surg 2007;245:36-43.
42.
Ueno S, Kubo F, Sakoda M, et al: Efficacy of anatomic resection vs nonanatomic resection for small nodular hepatocellular carcinoma based on gross classification. J Hepatobiliary Pancreat Surg 2008;15:493-500.
43.
Yamashita Y, Takeishi K, Tsuijita E, et al: Beneficial effects of preoperative lipiodolization for resectable large hepatocellular carcinoma (≥ 5 cm in diameter). J Surg Oncol 2012;106:498-503.
44.
Aoki T, Imamura H, Hasegawa K, et al: Sequential preoperative arterial and portal venous embolizations in patients with hepatocellular carcinoma. Arch Surg 2004;139:766-774.
45.
Schulze K, Gasch C, Staufer K, et al: Presence of EpCAM-positive circulating tumor cells as biomarker for systemic disease strongly correlates to survival in patients with hepatocellular carcinoma. Int J Cancer 2013;133:2165-2171.
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.